Literature DB >> 10586893

Therapeutic strategies for allergic diseases.

P J Barnes1.   

Abstract

Many drugs are now in development for the treatment of atopic diseases, including asthma, allergic rhinitis and atopic dermatitis. These treatments are based on improvements in existing therapies or on a better understanding of the cellular and molecular mechanisms involved in atopic diseases. Although most attention has been focused on asthma, treatments that inhibit the atopic disease process would have application to all atopic diseases, as they often coincide. Most of the many new therapies in development are aimed at inhibiting components of the allergic inflammatory response, but in the future there are real possibilities for the development of preventative and even curative treatments.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586893     DOI: 10.1038/35037026

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  28 in total

1.  Sequence-specific NMR resonance assignments for human interleukin-5.

Authors:  Hanqiao Feng; Debra L Banville; R D Guiles
Journal:  J Biomol NMR       Date:  2002-08       Impact factor: 2.835

2.  Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells.

Authors:  Matthew C Catley; Joanna E Chivers; Neil S Holden; Peter J Barnes; Robert Newton
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

3.  Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype.

Authors:  M Afanasyeva; Y Wang; Z Kaya; S Park; M J Zilliox; B H Schofield; S L Hill; N R Rose
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 4.  Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus.

Authors:  C N Serhan; N Chiang
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 5.  Chemokines and their receptors in the allergic airway inflammatory process.

Authors:  Juan Raymundo Velazquez; Luis Manuel Teran
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

6.  The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes.

Authors:  R Newton; L Cambridge; L A Hart; D A Stevens; M A Lindsay; P J Barnes
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

7.  Nicotine enhances murine airway contractile responses to kinin receptor agonists via activation of JNK- and PDE4-related intracellular pathways.

Authors:  Yuan Xu; Yaping Zhang; Lars-Olaf Cardell
Journal:  Respir Res       Date:  2010-01-29

Review 8.  p38 Mitogen activated protein kinase (MAPK): a new therapeutic target for reducing the risk of adverse pregnancy outcomes.

Authors:  Ramkumar Menon; John Papaconstantinou
Journal:  Expert Opin Ther Targets       Date:  2016-08-04       Impact factor: 6.902

9.  Nuclear factor-kappaB does not mediate the inhibitory effects of dexamethasone on granulocyte-macrophage colony-stimulating factor expression.

Authors:  Martin W Bergmann; Karl J Staples; Peter J Barnes; Robert Newton
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

10.  Effects of representative glucocorticoids on TNFα- and CD40L-induced NF-κB activation in sensor cells.

Authors:  Sirlene R Cechin; Peter Buchwald
Journal:  Steroids       Date:  2014-04-18       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.